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Introduction
TREM-1 (Triggering Receptor Expressed on Myeloid
Cells) amplifies Toll-like receptor (TLR) responses and
is a putative biomarker to diagnose VAP. It exists on
the surface of monocytes/macrophages (mTREM-1) and
neutrophils (nTREM-1) as well as a soluble receptor
(sTREM-1). Standalone levels of mTREM-1 in bronch-
oalveolar lavage fluid (BALF) and its BALF/blood ratio
are elevated in VAP (1). TREM-2 (a negative TLR regu-
lator) may also have a role in pneumonia (2), but there
is a paucity of data in humans.
Objectives
To measure temporal changes in monocytic/macrophage
and neutrophilic TREM-1 and TREM-2 surface receptor
levels in blood and BALF during VAP development and
resolution.
Methods
Serial receptor levels were assessed in 12 patients. 5 had
levels measured prior to development of VAP, 2 with
clinical worsening of VAP, 6 with VAP resolution and
in one patient changes were tracked in all three stages.
Patients were recruited in a teaching hospital ICU
(mixed medical, surgical and burns patients). Alternate
day phlebotomy and bronchoscopy were performed.
TREM-1 (12 patients) and TREM-2 levels (6 patients)
on neutrophils and monocytes/macrophages in blood
and BALF were assessed using flow-cytometry. VAP was
diagnosed using the clinical pulmonary infection score
(CPIS) and semi-quantitative microbiology and con-
firmed using HELICS criteria. In addition, peripheral
blood white cell count and CRP levels were determined.
Results
mTREM-1 in BALF and its BALF/blood ratio rose in four
out of the five patients each prior to VAP development
(static in one out of five). BALF mTREM-1 and its BALF/
blood ratio rose in both patients with worsening VAP
and fell in five out of six patients with resolving VAP
(static in the other). White cell count and CRP levels did
not correlate with VAP.
Neutrophilic TREM-1 changes in BALF broadly fitted
two patterns: either mirroring changes with mTREM-1
but with a lower magnitude, or falling with infection
development.
Considering TREM-2, BALF mTREM-2 either
remained similar or rose prior to VAP development of
VAP. The level rose with worsening VAP and fell with
resolution, akin to the changes in mTREM-1. For
nTREM-2, levels remained static prior to infection, but
rose during VAP development and resolution.
Conclusions
BALF mTREM-1 and its BALF/blood ratio rise and fall
with VAP development and resolution, highlighting the
potential role of TREM-1 in the pulmonary immune
response and its role as a putative biomarker for VAP
diagnosis. Monocyte and neutrophils differed in their
changes in TREM-1 and TREM-2 receptor levels over
time. TREM-1 and TREM-2 warrant further study in
patients with pneumonia.
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